Company Overview
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Why Investors Should Care
Return on capital employed stands at 141.6%.
Revenue has grown at a 380.1% CAGR over the past five years.
Trades at a P/E of 5.0, below the sector median of 24.8.
Operating margin of 80.2% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.18.
Recent Developments
- Dec 2025 Revenue of $38.47M (+380.1% YoY); net profit $-932.00K.
- Trailing 12 Months Year-on-year growth — revenue +2608.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 380.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 380.12% |
| 1 Year: | 2,608.80% |
Stock Price Performance
| 1 Year: | +15.16% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | +6.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)53.64 · Neutral
P/E of 5.03 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 141.6%.
- Compounding revenue at 380.1% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | APMD Apnimed, Inc. PHARMA | 28.79 | 5.03 | $1.15B | 0.00% | 141.62% | 0.25% | 380.12% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 3.13M | 84.81M |
| Cost of Revenue | 1.32M | 2.16M |
| Gross Profit | 1.81M | 82.65M |
| Operating Expenses | 28.93M | 14.61M |
| Operating Income | -27.11M | 68.04M |
| EBITDA | -27.11M | 68.05M |
| Interest Expense | - | - |
| Pretax Income | -26.68M | 70.37M |
| Tax Provision | 0 | 0 |
| Net Income | -28.65M | 70.37M |
| Diluted EPS | -1.00 | 2.12 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 8.01M | 38.47M |
| Cost of Revenue | 3.37M | 6.69M |
| Gross Profit | 4.64M | 31.77M |
| Operating Expenses | 118.88M | 85.59M |
| Operating Income | -114.23M | -53.82M |
| EBITDA | -114.21M | -53.79M |
| Interest Expense | - | - |
| Pretax Income | -108.55M | -932.00K |
| Tax Provision | 51.00K | 0 |
| Net Income | -111.31M | -932.00K |
| Diluted EPS | -3.87 | -0.03 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 109.22M | 72.87M |
| Current Assets | 73.25M | 45.05M |
| Cash & Equivalents | 68.35M | 41.89M |
| Inventory | - | - |
| Receivables | 1.11M | 959.00K |
| Total Liabilities | 357.84M | 445.66M |
| Current Liabilities | 42.36M | 110.88M |
| Long Term Debt | - | 40.65M |
| Total Debt | 1.09M | 41.52M |
| Total Equity | -248.62M | -372.78M |
| Shares Outstanding | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -110.21M | -77.83M |
| Investing Cash Flow | 151.96M | 0 |
| Financing Cash Flow | 51.00K | 51.37M |
| Capital Expenditure | -70.00K | - |
| Free Cash Flow | -110.28M | -77.83M |
| Net Change in Cash | 41.80M | -26.46M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | 58.0% | 82.6% |
| Operating Margin % | -1,425.8% | -139.9% |
| Net Margin % | -1,389.2% | -2.4% |
| ROE % | 44.8% | 0.3% |
| ROCE % | -170.8% | 141.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APMD
Apnimed, Inc. - Common Stock (Nasdaq:APMD) Stock Quote - FinancialContent
<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE1CZERFSWpGX3RiSDM3LUx6amFvUHZuWWU5VGNWbDV1NWhVNWRFTWRlQUc5QURET3NpZkFlb1JJeWNKY01JZ08yVWduZUJlU3VRUERWVHlCeEJ2dlNRZDhCZGJJQ3dYY0ltclFLN0J1SW01NWRXaWpkbEE4QQ?oc=5" target="_blank">A…
One-time gains push Apnimed (APMD) into the black - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPN0o1VFFVTUh0ekhDQlVhZkV3dmxUQnB1dm5iTTFuZU1EVmFnX0NJeVBrVEwyd2ladjBQeWNxTXhxMm9JY2ZhTUlIN09Cc2hreFBkY0FmaEJYZ2xQUnRuSWZhM2FXTVFMS3MyT3hSdlhuZVNzd1p6SGZ3VUJnUTkyUV9yUEVOZmJEUzl6Un…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFA5eVdQallsR0pqQnZOMndKZy0xYnhHdjBSWWk3VS1sRkg2NkhRRW14OWJqa0RyYVpHVXFzRG5UdEFkT0kweDVHU2FDTF9aNjkw?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Apnimed Q2 Swings to Earnings, Revenue Declines - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNcnV2bTV6QXluNThOenBINTdLRUl1ZloyYkZfNjBqTkF2M29hZ2Y0Mkg0R1NJQXRoVXhHcjB1dHhxeDMxUVdJaHI3bjBzU3M4S3VQVHRlVWNhZk01R2pNNTlJbkxkRlhXQUcwZW5xamZUZDFKLVZXR0MtVE82bFUyZTlZcFY2NFctcnFzU2…
LifeSci Capital Initiates Apnimed(APMD.US) With Buy Rating, Announces Target Price $50 - Moomoo
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOZW0wb0JWeDduSUg5MkRrZ2w0ekx2Ml9aVmNJRFNsQms5bnF2cFdXVmd1ZGlHa1ZtT1gtX0czN3hjcFowQUpfR052WFNzLTBJMVZwVXN5Rm81azY4M1d2RzBJXzVCamhqQkVXdHh0d0p6bGZyMUJaV1d2MWJqRThmSVpCMzRhajkwd3BLY3…
Apnimed (APMD) Joins The NASDAQ Composite Index - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPR2pnTTV1U3h0RklCWks4UTJFVTVpYVpKQ25YY3haZU9NX2EtU19qNlZ6TEszVVp6R3ZETWhYMlBoUlNDOFF2NmRCd2IxcW5COUxxN3NpYWJ6bkpYc1lITnY2azNkUXBVMUhEZmJfd1ZCcUV1SER3VG5mdUp1d0czcnJ2VGQ2VHFMSzFGX2…
APMD — Frequently Asked Questions
What is the current share price of Apnimed, Inc. (APMD)?
As of 2026-09-19 21:16 PDT, Apnimed, Inc. (APMD) trades at $28.79 on NasdaqGS. Its 52-week range is $24.87 to $32.55.
What is the market capitalisation of APMD?
Apnimed, Inc. (APMD) has a market capitalisation of $1.15B on NasdaqGS.
What is the P/E ratio of APMD?
APMD trades at a trailing price-to-earnings (P/E) ratio of 5.03. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.52.
What is the return on equity (ROE) of APMD?
APMD has a return on equity (ROE) of 0.25%. Its return on capital employed (ROCE) is 141.62%.
Is APMD a good stock to buy?
This page provides a data-driven analysis of Apnimed, Inc. (APMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.